GPT and metabolic dysfunction-associated steatohepatitis: In a longer-term 24-week study in NASH patients, daily administration of 1 mg aldafermin led to an approximately 30% placebo-adjusted relative reduction in liver fat while reducing ALT by about 45% from baseline.